Update on the Management of ABCA4 Retinopathy (Stargardt Disease)

ABCA4-associated retinopathies (Stargardt disease) are the most common inherited macular dystrophy and a leading cause of early onset central vision loss. Biallelic pathogenic variants in the ABCA4 gene cause impaired clearance of retinoid byproducts, leading to toxic bisretinoid accumulation, retinal pigment epithelium dysfunction, and progressive photoreceptor degeneration. Clinical presentation and disease progression are highly heterogeneous, largely influenced by genotype, age at onset, and environmental modifiers. Current management remains supportive and includes low-vision rehabilitation and counseling. Recent advances in molecular genetics, retinal imaging, and translational science have substantially expanded the therapeutic pipeline for ABCA4 retinopathy. Disease-modifying strategies under active investigation include visual-cycle modulation, deuterated vitamin A analogs, retinol-binding protein antagonists, gene augmentation and editing approaches, antisense oligonucleotides, and cell-based regenerative therapies. Several pharmacologic agents have demonstrated promising structural outcomes in clinical trials, while gene-based and regenerative approaches continue to evolve amid challenges related to gene size, delivery efficiency, and long-term safety. Optogenetic therapy has emerged as a gene-agnostic option for functional vision restoration in advanced disease stages. This review provides an integrated overview of ABCA4 retinopathy, summarizing disease mechanisms, current management strategies, emerging therapies, and the evolving clinical trial landscape. Emphasis is placed on stage-adapted treatment paradigms, appropriate monitoring endpoints, and the potential role of combination therapies. Ongoing innovation and precision-based approaches offer cautious optimism for durable disease modification and functional preservation in this currently untreatable condition. Stargardt disease is the most common inherited condition that damages the center of the retina and causes vision loss, often beginning in childhood or early adulthood. The disease results from changes in a gene called ABCA4, which normally helps to remove waste products created when the eye processes light. When this system fails, harmful substances build up in the retina. These substances, known as lipofuscin, damage light-sensing cells and lead to a gradual loss of central vision. At present, no approved treatment can stop or reverse this process. Researchers have developed several new treatment strategies based on a better understanding of how the disease works. Some medicines aim to slow the formation of toxic byproducts in the retina by modifying vitamin A metabolism. Early clinical trials suggest that certain compounds may slow the growth of retinal damage in patients with milder disease. Other approaches attempt to replace or repair the faulty ABCA4 gene to address the root cause of the disorder. These gene-based therapies have reduced harmful buildup in animal studies and are now being tested in people. For patients with advanced disease, where many light-sensing cells have already been lost, scientists are exploring cell transplantation and optogenetics. Optogenetics is a technique that makes remaining retinal cells sensitive to light, enabling the restoration of some visual function. Future treatment will likely combine several strategies tailored to the stage of disease, with the goal of preserving vision for as long as possible and restoring function when feasible.